A Japan nationwide web-based survey of patient preference for renal denervation for hypertension treatment
Open Access
- 17 October 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Hypertension Research
- Vol. 45 (2), 232-240
- https://doi.org/10.1038/s41440-021-00760-9
Abstract
Renal denervation is a potential alternative to antihypertensive drug therapy. However, data on patient preference for this treatment option are limited and there are no data specifically from Asian patients. This study evaluated patient preference for renal denervation in patients with hypertension from Japan. Patients were a subset of those who participated in a March 2020 online electronic survey of patients with hypertension who had regularly visited medical institutions for treatment, were receiving antihypertensive drug therapy and had home blood pressure recordings available. The survey included a question about patient preference for treatment with renal denervation. A total of 2,392 patients were included (66% male, mean age 59.8 ± 11.6 years, mean duration of hypertension 11.4 ± 9.5 years). Preference for renal denervation was expressed by 755 patients (31.6%), and was higher in males than in females, in younger compared with older patients, in those with higher versus lower blood pressure, in patients who were less adherent versus more adherent to antihypertensive drug therapy, and in those who did rather than did not have antihypertensive drug-related side effects. Significant predictors of preference for renal denervation on logistic regression analysis were younger patient age, male sex, higher home or office systolic blood pressure, poor antihypertensive drug adherence, the presence of heart failure, and the presence of side effects during treatment with antihypertensive drugs. Overall, a relevant proportion of Japanese patients with hypertension expressed a preference for renal denervation. This should be taken into account when making shared decisions about antihypertensive drug therapy.Keywords
This publication has 40 references indexed in Scilit:
- SYMPLICITY HTN-Japan – First Randomized Controlled Trial of Catheter-Based Renal Denervation in Asian Patients –Circulation Journal, 2015
- Home Blood Pressure and Cardiovascular Outcomes in Patients During Antihypertensive TherapyHypertension, 2014
- A Controlled Trial of Renal Denervation for Resistant HypertensionThe New England Journal of Medicine, 2014
- First-in-man safety evaluation of renal denervation for chronic systolic heart failure: Primary outcome from REACH-Pilot studyInternational Journal of Cardiology, 2013
- Point: Chronic Activation of the Sympathetic Nervous System is the Dominant Contributor to Systemic HypertensionJournal of Applied Physiology, 2010
- Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trialThe Lancet, 2010
- The Hypertension Paradox — More Uncontrolled Disease despite Improved TherapyThe New England Journal of Medicine, 2009
- Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort studyThe Lancet, 2009
- Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studiesThe Lancet, 2002
- Racial Differences in Drug ResponseThe New England Journal of Medicine, 1989